Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
275 studies found for:    Open Studies | "Carcinoma, Renal Cell"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Renal Cell"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Immunotherapy Study for Metastatic Renal Cell Cancer
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Clear-cell Renal Cancer;   Recurrent Renal Cell Carcinoma;   Refractory Renal Cell Carcinoma;   Metastatic Kidney Cancer
Intervention: Biological: HyperAcute®-Renal (HAR) Immunotherapy
2 Recruiting AMG 172 First in Human Study in Patients With Kidney Cancer
Conditions: Renal Cell Adenocarcinoma;   Clear Cell Renal Carcinoma;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: AMG 172
3 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
4 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
5 Unknown  microRNA Expression in Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention:
6 Recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Conditions: Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment;   Biological: AGS-003
7 Unknown  Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Genetic: mutation analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Drug: sunitinib malate;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
8 Recruiting Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY 43-9006)
9 Recruiting Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Device: DCE-MRI and Quantitative Doppler Ultrasound
10 Recruiting Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib followed by everolimus
11 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475
12 Recruiting Interleukin-2 in Metastatic Kidney Cancer
Conditions: Renal Cell Cancer Metastatic;   Kidney Cancer Metastatic
Intervention: Drug: Interleukin-2
13 Not yet recruiting A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Interventions: Radiation: Stereotactic Radiosurgery;   Drug: Pazopanib Hydrochloride
14 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Intervention: Drug: Pazopanib Hydrochloride
15 Recruiting Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: panobinostat;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: liquid chromatography;   Other: mass spectrometry;   Other: enzyme-linked immunosorbent assay;   Other: immunohistochemistry staining method
16 Recruiting A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
Conditions: ccRCC;   RCC;   Kidney Cancer;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: PT2385 Tablets
17 Recruiting Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
18 Recruiting Perfusion CT in Predicting Response to Treatment in Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: perfusion;   Procedure: computed tomography;   Other: laboratory biomarker analysis
19 Recruiting Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer
Interventions: Biological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
20 Recruiting Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: pharmacogenomic studies

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years